Christian Behrenbruch
Gründer bei TELIX PHARMACEUTICALS LIMITED
Vermögen: 222 Mio $ am 30.04.2024
Profil
Christian P.
Behrenbruch is the founder.
He founded ImaginAb, Inc. in 2007, where he served as the Chief Executive Officer & Director until 2015.
He also founded Telix Pharmaceuticals Ltd.
in 2015 and currently holds the position of Group CEO, MD & Executive Director.
Dr. Behrenbruch is also the founder of Amplia Therapeutics Pty Ltd.
Dr. Behrenbruch's current jobs include being the Chairman of Monash Engineering Foundation, the Managing Director of Irukandji Research Pty Ltd., and a Director at Advanced Nuclear Medicine Ingredients SA since 2018.
Dr. Behrenbruch's former jobs include being the Chief Executive Officer of Fibron Technologies, Inc. from 2008 to 2011, the Chief Executive Officer of Mirada Solutions Ltd.
from 2001 to 2002, the Chairman of Cell Therapies Pty Ltd.
from 2012 to 2014, a Non-Executive Director at Dominion Minerals Ltd.
from 2015 to 2021, a Director at Oncidium Foundation, an Independent Director at Amplia Therapeutics Ltd.
from 2016 to 2020, the Director of Siemens Molecular Imaging, Inc. from 2005 to 2006, the Director of Momentum Biosciences LLC from 2007 to 2009, the Director of Radius Health, Inc. from 2009 to 2011, and the President of CTI Molecular Imaging, Inc. from 2003 to 2006.
Dr. Behrenbruch's education includes a graduate degree from the University of Melbourne, a doctorate degree from the University of Oxford, an MBA from New York University, and an MBA from École des Hautes Études Commerciales de Paris.
Dr. Behrenbruch is also the founder of Amplia Therapeutics Pty Ltd...
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
24.01.2024 | 22 675 000 ( 6,86% ) | 222 Mio $ | 30.04.2024 |
Aktive Positionen von Christian Behrenbruch
Unternehmen | Position | Beginn |
---|---|---|
TELIX PHARMACEUTICALS LIMITED | Gründer | 01.11.2015 |
Advanced Nuclear Medicine Ingredients SA
Advanced Nuclear Medicine Ingredients SA Wholesale DistributorsDistribution Services Advanced Nuclear Medicine Ingredients SA engages in the distribution of pharmaceutical ingredients. Its products and services include toward cold kits for PET, custom peptide synthesis, new theranostic cold kits and theranostic development. The company was founded by Bruno Colard, Severine Plunus, Laurent Bodson, Monique Body, Amadeo Falcone, Sabine Lurson, Gael Minon, Michel Falcone, Vanessa Charlier, Chantal Riviere, Jean Francois Kaisin, Samuel Voccia, and Ludovic Wouters on March 27, 2015 and is headquartered in Liege, Belgium. | Direktor/Vorstandsmitglied | 21.12.2018 |
Amplia Therapeutics Pty Ltd.
Amplia Therapeutics Pty Ltd. Pharmaceuticals: MajorHealth Technology Amplia Therapeutics Pty Ltd. manufactures pharmaceutical products. The company was founded by Chris Behrenbruch and is headquartered in Australia. | Gründer | - |
Irukandji Research Pty Ltd. | Corporate Officer/Principal | - |
Monash Engineering Foundation | Vorsitzender | - |
Ehemalige bekannte Positionen von Christian Behrenbruch
Unternehmen | Position | Ende |
---|---|---|
DOMINION MINERALS LIMITED | Direktor/Vorstandsmitglied | 28.05.2021 |
AMPLIA THERAPEUTICS LIMITED | Direktor/Vorstandsmitglied | 01.02.2020 |
ImaginAb, Inc.
ImaginAb, Inc. Medical SpecialtiesHealth Technology ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA. | Gründer | 01.02.2015 |
Cell Therapies Pty Ltd. | Vorsitzender | 01.07.2014 |
░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Christian Behrenbruch
University of Melbourne | Graduate Degree |
University of Oxford | Doctorate Degree |
New York University | Masters Business Admin |
École des Hautes Études Commerciales de Paris | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
DOMINION MINERALS LIMITED | Non-Energy Minerals |
AMPLIA THERAPEUTICS LIMITED | Health Technology |
TELIX PHARMACEUTICALS LIMITED | Health Technology |
Private Unternehmen | 13 |
---|---|
CTI Molecular Imaging, Inc.
CTI Molecular Imaging, Inc. Medical SpecialtiesHealth Technology CTI Molecular Imaging, Inc. makes positron emission tomography (PET) scanners that provide early detection of cancer, cardiac disease and neurological disorders. The company's PETNet unit makes radiopharmaceuticals and distributes them through more than 40 'radiopharmacies' across the US as well as in the UK and South Korea. CTI also makes detector materials used in the PET scanners. CTI markets its products to hospitals, universities and imaging and cancer treatment centers. The company is headquartered in Knoxville, TN | Health Technology |
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Mirada Solutions Ltd.
Mirada Solutions Ltd. Packaged SoftwareTechnology Services Mirada Solutions Ltd. develops software applications for medical imaging. The company develops quantitative image analysis tools for medical imaging workstations, OEM imaging platforms, and pharmaceutical research which are used for detection, diagnosis, and management of disease by applying powerful algorithms, quantification tools, and image analysis. Mirada Solutions is headquartered in Oxford, UK | Technology Services |
Cell Therapies Pty Ltd. | |
Siemens Molecular Imaging, Inc. | |
Fibron Technologies, Inc.
Fibron Technologies, Inc. Chemicals: SpecialtyProcess Industries Fibron Technologies, Inc. develops organic polymer materials. | Process Industries |
ImaginAb, Inc.
ImaginAb, Inc. Medical SpecialtiesHealth Technology ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA. | Health Technology |
Momentum Biosciences LLC
Momentum Biosciences LLC Investment ManagersFinance Part of Teladoc Health, Inc., Momentum Biosciences LLC is a company that provides expressive art therapy services. The company is based in Culver City, CA. The company's therapists are certified professionals and they offer counseling services at a cost of approximately $240-$360 per month. | Finance |
Oncidium Foundation | |
Irukandji Research Pty Ltd. | |
Advanced Nuclear Medicine Ingredients SA
Advanced Nuclear Medicine Ingredients SA Wholesale DistributorsDistribution Services Advanced Nuclear Medicine Ingredients SA engages in the distribution of pharmaceutical ingredients. Its products and services include toward cold kits for PET, custom peptide synthesis, new theranostic cold kits and theranostic development. The company was founded by Bruno Colard, Severine Plunus, Laurent Bodson, Monique Body, Amadeo Falcone, Sabine Lurson, Gael Minon, Michel Falcone, Vanessa Charlier, Chantal Riviere, Jean Francois Kaisin, Samuel Voccia, and Ludovic Wouters on March 27, 2015 and is headquartered in Liege, Belgium. | Distribution Services |
Amplia Therapeutics Pty Ltd.
Amplia Therapeutics Pty Ltd. Pharmaceuticals: MajorHealth Technology Amplia Therapeutics Pty Ltd. manufactures pharmaceutical products. The company was founded by Chris Behrenbruch and is headquartered in Australia. | Health Technology |
Monash Engineering Foundation |